173 related articles for article (PubMed ID: 15721380)
1. Liposomalized oligopeptides in cancer therapy.
Asai T; Oku N
Methods Enzymol; 2005; 391():163-76. PubMed ID: 15721380
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
3. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
4. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
5. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Asai T; Shimizu K; Kondo M; Kuromi K; Watanabe K; Ogino K; Taki T; Shuto S; Matsuda A; Oku N
FEBS Lett; 2002 Jun; 520(1-3):167-70. PubMed ID: 12044891
[TBL] [Abstract][Full Text] [Related]
6. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Guo P; Song S; Li Z; Tian Y; Zheng J; Yang X; Pan W
Int J Pharm; 2015; 486(1-2):356-66. PubMed ID: 25840274
[TBL] [Abstract][Full Text] [Related]
8. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug.
Shimizu K; Sawazaki Y; Tanaka T; Asai T; Oku N
Biol Pharm Bull; 2008 Jan; 31(1):95-8. PubMed ID: 18175949
[TBL] [Abstract][Full Text] [Related]
9. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate.
Maeda N; Takeuchi Y; Takada M; Namba Y; Oku N
Bioorg Med Chem Lett; 2004 Feb; 14(4):1015-7. PubMed ID: 15013013
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.
Maeda N; Miyazawa S; Shimizu K; Asai T; Yonezawa S; Kitazawa S; Namba Y; Tsukada H; Oku N
Biol Pharm Bull; 2006 Sep; 29(9):1936-40. PubMed ID: 16946513
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
Ichikawa K; Hikita T; Maeda N; Yonezawa S; Takeuchi Y; Asai T; Namba Y; Oku N
Biochim Biophys Acta; 2005 May; 1669(1):69-74. PubMed ID: 15843001
[TBL] [Abstract][Full Text] [Related]
13. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
[TBL] [Abstract][Full Text] [Related]
14. Liposomes modified with a synthetic Arg-Gly-Asp mimetic inhibit lung metastasis of B16BL6 melanoma cells.
Kurohane K; Namba Y; Oku N
Life Sci; 2000 Dec; 68(3):273-81. PubMed ID: 11191643
[TBL] [Abstract][Full Text] [Related]
15. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model.
Yonezawa S; Asai T; Oku N
J Control Release; 2007 Apr; 118(3):303-9. PubMed ID: 17275944
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
Li C; Shen J; Wei X; Xie C; Lu W
J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
[TBL] [Abstract][Full Text] [Related]
17. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
19. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
[TBL] [Abstract][Full Text] [Related]
20. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]